Skip to main content

Table 3 Univariate and multivariate Cox Proportional hazard ratios (HR) for disease recurrence

From: Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer

 

Univariate

Multivariate

HR (95% CI)

p-value

HR (95% CI)

p-value

Treatment intervala

 Group 1

1 (reference)

   

 Group 2

1.113 (0.680–1.822)

0.670

  

Age

 < 65 yr

1 (reference)

   

 ≥ 65 yr

0.679 (0.271–1.701)

0.409

  

CA-125

 < 40 U/mL

1 (reference)

 

1 (reference)

 

 ≥ 40 U/mL

1.976 (1.187–3.287)

0.009

1.620 (0.954–2.749)

0.074

Histology

 Serous

1 (reference)

   

 Non-serous

1.081 (0.597–1.956)

0.798

  

Surgery

 Laparoscopy

1 (reference)

   

 Laparotomy

1.657 (0.900–3.051)

0.105

  

ASA scoreb

 1

1 (reference)

   

 2, 3

0.808 (0.458–1.426)

0.462

  

Residual diseasec

 R0

1 (reference)

 

1 (reference)

 

 R1, R2

2.366 (1.384–4.046)

0.002

2.031 (1.161–3.554)

0.013

Platinum free interval

 6-12mo

1 (reference)

 

1 (reference)

 

 over 12mo

0.509 (0.276–0.940)

0.031

0.582 (0.309–1.095)

0.093

Recurrence no.

 1st recur

1 (reference)

   

 2nd recur

0.967 (0.416–2.247)

0.938

  
  1. aEnrolled patients were divided into two groups; Group1 (treatment interval ≤ 10 days) and Group2 (treatment interval > 10 days)
  2. bASA score, American Society of Anaesthesiologists score
  3. cThe level of residual disease after SCS was divided into no gross (R0), 1–9 mm (R1), and equal to or more than 10 mm residual disease (R2)
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us